#### <sup>1</sup>**Title page**

- <sup>2</sup>Common pathogenic mechanisms for COVID-19 and differentiated thyroid cancer: a
- 3 proteomic analysis 4
- 4
- 5 Hanqing Liu <sup>1,\*</sup>, Jiaxi Wang <sup>1,\*</sup>, Dan Yang <sup>2,\*</sup>, Chuang Chen <sup>1,\*</sup>
- 
- 7 7 Addresses<br>8  $\frac{1}{2}$  Denartme
- <sup>1</sup> Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan,
- 9 430060, Hubei, People's Republic of China.<br>10  $^2$  Department of Cardiology, the Second Affi
- 2 Department of Cardiology, the Second Affiliated Hospital of Chongqing Medical University,
- 11 Chongqing 400010, People's Republic of China.<br>12
- 
- 12 <sup>13</sup> \* The two authors contributed equally to the work<br>14
- 
- 15  $15$   $*$  Correspondence:
- 16 Prof. Chuang Chen,<br>17 Department of Thyre
- 17 Department of Thyroid and Breast Surgery,<br>18 Renmin Hospital of Wuhan University.
- 18 Renmin Hospital of Wuhan University,<br>19 Wuhan University at Jiefang Road 238.
- 19 Wuhan University at Jiefang Road 238, Wuhan 430060, RP China.<br>20 Tel: +86 27 88041911: Fax: +86 27 88041911. (Email: chenc24690)
- 20 Tel: +86 27 88041911; Fax: +86 27 88041911. (Email: chenc2469@163.com)<br>21
- 
- 22 22 Dr. Dan Yang,<br>23 Department of
- 23 Department of Cardiology,<br>24 The Second Affiliated Host
- 24 The Second Affiliated Hospital of Chongqing Medical University,<br>25 Chongqing Medical University, Chongqing 400010, RP China.
- 25 Chongqing Medical University, Chongqing 400010, RP China.<br>26 Tel: +86 023 68811360: Fax: +86 023 68811360. (Email: DrYa
- 26 Tel: +86 023 68811360; Fax: +86 023 68811360. (Email: DrYang@hospital.cqmu.edu.cn)<br>27
- 
- 28 28

#### <sup>29</sup>**Abstract and keywords**

### 30 Abstract<br>31 Backgrou

31 Background: Previous studies have proved that viral infection might have potential<br>32 associations with differentiated thyroid cancer. COVID-19 has spread to hundreds of millions 32 associations with differentiated thyroid cancer. COVID-19 has spread to hundreds of millions<br>33 of individuals since Dec 2019. This study aimed to investigate the common pathogenic 33 of individuals since Dec 2019. This study aimed to investigate the common pathogenic<br>34 mechanisms of differentiated thyroid cancer and SARS-CoV-2 infection in thyroid tissues. 34 mechanisms of differentiated thyroid cancer and SARS-CoV-2 infection in thyroid tissues.<br>35 Methods: The proteomic profiles of COVID-19 and differentiated thyroid cancer v

35 Methods: The proteomic profiles of COVID-19 and differentiated thyroid cancer were<br>36 downloaded from iProx database and were analyzed for differentially expressed proteins. 36 downloaded from iProx database and were analyzed for differentially expressed proteins.<br>37 After the common proteins were identified using the Venn diagram, gene ontology and 37 After the common proteins were identified using the Venn diagram, gene ontology and<br>38 pathway enrichment analysis were performed. Subsequently, a protein-protein interaction 38 pathway enrichment analysis were performed. Subsequently, a protein-protein interaction<br>39 network was constructed and hub genes were identified with eight algorithms. The diagnostic 39 network was constructed and hub genes were identified with eight algorithms. The diagnostic<br>40 performance of hub genes was tested with the receiver operator characteristics curve. The 40 performance of hub genes was tested with the receiver operator characteristics curve. The<br>41 associations between hub genes and diseases were evaluated with the Comparative 41 associations between hub genes and diseases were evaluated with the Comparative<br>42 Toxicogenomics Database.

42 Toxicogenomics Database.<br>43 Results: Fortv-nine comm 43 Results: Forty-nine common differentially expressed proteins were identified. Functional<br>44 analysis revealed that the metabolism and transport of lipid and cholesterol and coagulation 44 analysis revealed that the metabolism and transport of lipid and cholesterol and coagulation<br>45 by process were the main common biological activities affected by the two diseases. In addition, 45 process were the main common biological activities affected by the two diseases. In addition,<br>46 twelve genes, including AGT, AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, 46 twelve genes, including AGT, AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, <br>47 SERPINC1, TF and TTR, were identified as the hub genes. These genes could serve as

47 SERPINC1, TF and TTR, were identified as the hub genes. These genes could serve as diagnostic markers for COVID-19 and differentiated thyroid cancers. 48 diagnostic markers for COVID-19 and differentiated thyroid cancers.<br>49 Conclusion: The current study revealed common pathogenic mechan

49 Conclusion: The current study revealed common pathogenic mechanisms of COVID-19 and<br>50 differentiated thyroid cancer. The concomitant infection of SARS-CoV-2 might exert adverse

50 differentiated thyroid cancer. The concomitant infection of SARS-CoV-2 might exert adverse<br>51 effects on patients with thyroid cancers.

- 51 effects on patients with thyroid cancers.<br>52
- 

52 53 Keywords: DTC, coronavirus disease 2019, SARS-CoV-2, bioinformatics 54

#### <sup>56</sup>**1 Introduction**

57 Thyroid cancer is the most common endocrine malignancy all over the world (1). Its<br>58 incidence has doubled since the mid-1990s (2, 3). Although thyroid cancer consists of several 58 incidence has doubled since the mid-1990s  $(2, 3)$ . Although thyroid cancer consists of several<br>59 histopathological types, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) 59 histopathological types, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC)<br>60 account for more than 80% of total cases. PTC and FTC are also categorized as differentiated 60 account for more than 80% of total cases. PTC and FTC are also categorized as differentiated thyroid cancers.<br>61 thyroid cancer (DTC) in contrast with poorly differentiated and anaplastic thyroid cancers. 61 thyroid cancer (DTC) in contrast with poorly differentiated and anaplastic thyroid cancers.<br>62 Notably, DTC contributes to the maiority of incidence elevation (4). While the incidence of 62 Notably, DTC contributes to the majority of incidence elevation (4). While the incidence of 63 other histopathological subtypes remains almost unaltered, the incidence of DTC increased by 63 other histopathological subtypes remains almost unaltered, the incidence of DTC increased by<br>64 300% since 1975 (5). The elevation may be explained by both increasing exposure to risk 64 300% since 1975 (5). The elevation may be explained by both increasing exposure to risk<br>65 factors and the application of ultrasound devices with high resolution. 65 factors and the application of ultrasound devices with high resolution.<br>66 The risk factors for thyroid cancers are various, including radia

66 The risk factors for thyroid cancers are various, including radiation, iodine deficiency,<br>67 genetic susceptibility, etc. More recently, the association between thyroid cancer and viral 67 genetic susceptibility, etc. More recently, the association between thyroid cancer and viral<br>68 infection has been noticed. Enstein-Barr virus is a well-known human tumor virus associated 68 infection has been noticed. Epstein-Barr virus is a well-known human tumor virus associated<br>69 with multiple malignancies, including nasopharyngeal carcinoma. Hodgkin's lymphoma and 69 with multiple malignancies, including nasopharyngeal carcinoma, Hodgkin's lymphoma and<br>70 Burkitt's lymphoma. A retrospective clinical study using *in situ* hybridization showed that the 70 Burkitt's lymphoma. A retrospective clinical study using *in situ* hybridization showed that the<br>71 detection of Epstein-Barr virus (EBV) was significantly higher in thyroid cancer tissues 71 detection of Epstein-Barr virus (EBV) was significantly higher in thyroid cancer tissues<br>72 compared with paired adiacent normal tissues (6). Similar results were verified with serologic 72 compared with paired adjacent normal tissues (6). Similar results were verified with serologic<br>73 assays in another study (7). In addition, the potential link between hepatitis C virus and 73 assays in another study (7). In addition, the potential link between hepatitis C virus and<br>74 thyroid cancer has been revealed. A higher prevalence of chronic hepatitis was found in 74 thyroid cancer has been revealed. A higher prevalence of chronic hepatitis was found in<br>75 patients with thyroid cancers (8). Similar phenomena were also found in patients infected 75 patients with thyroid cancers (8). Similar phenomena were also found in patients infected<br>76 with hepatitis B virus (9, 10), human erythrovirus B19 (11, 12), cytomegalovirus (13), and 76 with hepatitis B virus (9, 10), human erythrovirus B19 (11, 12), cytomegalovirus (13), and<br>77 human T-cell lymphotropic virus (14). Of interest, these viruses are also related to 77 human T-cell lymphotropic virus (14). Of interest, these viruses are also related to<br>78 autoimmune thyroiditis (15). The carcinogenetic mechanism of these viruses, if exists, is most 78 autoimmune thyroiditis (15). The carcinogenetic mechanism of these viruses, if exists, is most<br>79 likely to be chronic inflammation. Some virus proteins, such as latent membrane protein 79 likely to be chronic inflammation. Some virus proteins, such as latent membrane protein<br>80 released by EBV, can exert effects on cell cycle-related intracellular proteins. Inferably, viral 80 released by EBV, can exert effects on cell cycle-related intracellular proteins. Inferably, viral<br>81 oncogene may also be a potential mechanism in the carcinogenesis of thyroid cancer. 81 oncogene may also be a potential mechanism in the carcinogenesis of thyroid cancer.<br>82 Since the first case was reported in Wuhan. China in Dec 2019, coronavirus dise

82 Since the first case was reported in Wuhan, China in Dec 2019, coronavirus disease 2019<br>83 (COVID-19) has spread to 228 countries and territories. More than six hundred million cases 83 (COVID-19) has spread to 228 countries and territories. More than six hundred million cases<br>84 were confirmed and its mortality is approximately 1% (16). Undoubtedly, the real incidence is 84 were confirmed and its mortality is approximately 1% (16). Undoubtedly, the real incidence is<br>85 much higher than the reported number since nucleic acid tests and antigen assays are not 85 much higher than the reported number since nucleic acid tests and antigen assays are not<br>86 performed in all suspected patients. The pathogen of COVID-19 is severe acute respiratory 86 performed in all suspected patients. The pathogen of COVID-19 is severe acute respiratory<br>87 syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus can invade peripheral tissue 87 syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus can invade peripheral tissue<br>88 cells via the angiotensin-converting enzyme 2 (ACE2) and cause multiple organ dysfunctions 88 cells via the angiotensin-converting enzyme 2 (ACE2) and cause multiple organ dysfunctions,<br>89 including lung, kidney and heart (17). Direct viral infection, cytokine storm, down-regulation 89 including lung, kidney and heart (17). Direct viral infection, cytokine storm, down-regulation<br>90 of ACE2 and endothelial cell damage are supposed to be the pathogenic mechanisms (18-20). 90 of ACE2 and endothelial cell damage are supposed to be the pathogenic mechanisms (18-20).<br>91 Of interest, current evidences suggest that potential linkages may exist between thyroid

91 Of interest, current evidences suggest that potential linkages may exist between thyroid<br>92 cancer and COVID-19. A multicenter cohort study in Los Angeles revealed a positive 92 cancer and COVID-19. A multicenter cohort study in Los Angeles revealed a positive<br>93 correlation between comorbid conditions and risk of hospitalization from SARS-CoV-2 93 correlation between comorbid conditions and risk of hospitalization from SARS-CoV-2<br>94 infection in thyroid cancer patients (21). Another retrospective study revealed a small but 94 infection in thyroid cancer patients (21). Another retrospective study revealed a small but<br>95 significant elevation of DTC after the outbreak of the pandemic, although the results were 95 significant elevation of DTC after the outbreak of the pandemic, although the results were<br>96 hard to explain and confounding factors needed to be explored (22). Autoimmune thyroid 96 hard to explain and confounding factors needed to be explored (22). Autoimmune thyroid<br>97 diseases are known to increase the risk of thyroid cancer. Previous reports have shown that <sup>97</sup>diseases are known to increase the risk of thyroid cancer. Previous reports have shown that

98 the relapse or new diagnosis of autoimmune thyroid diseases could be triggered within one<br>99 month after SARS-CoV-2 infection (23). Some researchers have assumed that thyroid 99 month after SARS-CoV-2 infection (23). Some researchers have assumed that thyroid<br>100 inflammation could be induced by COVID-19-related immune response (24). Since the ACE2 100 inflammation could be induced by COVID-19-related immune response (24). Since the ACE2<br>101 expression levels are higher in thyroid tissue in comparison with lung (25), the coronavirus 101 expression levels are higher in thyroid tissue in comparison with lung (25), the coronavirus<br>102 might damage normal thyroid tissues and subsequently induce carcinogenesis. Currently, little 102 might damage normal thyroid tissues and subsequently induce carcinogenesis. Currently, little<br>103 is known about the association between COVID-19 and DTC from a molecular aspect. 103 is known about the association between COVID-19 and DTC from a molecular aspect.<br>104 The aim of this study is to evaluate the potential common molecular mechanisms for 104 The aim of this study is to evaluate the potential common molecular mechanisms for DTC<br>105 and COVID-19 using bioinformatic tools.

- 105 and COVID-19 using bioinformatic tools.<br>106
- 

#### <sup>107</sup>**2 Materials and methods**

#### 108 2.1 Data acquisition

109 Two proteomic expression profiles were selected and downloaded from iProX database<br>110 (Figure 1) (26). iProX database is a public platform for collecting and sharing proteomics 110 (Figure 1) (26). iProX database is a public platform for collecting and sharing proteomics<br>111 datasets. The two proteomic datasets were both released by Guo's lab at Westlake University 111 datasets. The two proteomic datasets were both released by Guo's lab at Westlake University<br>112 (27, 28). The tissue bionsy samples were processed using the pressure cycling technique 112 (27, 28). The tissue biopsy samples were processed using the pressure cycling technique<br>113 protocol to separate small amounts of components. Subsequently, data-independent 113 protocol to separate small amounts of components. Subsequently, data-independent acquisition mass spectrometry was used to analyze the prepared samples at high throughput. 114 acquisition mass spectrometry was used to analyze the prepared samples at high throughput.<br>115 The IPX0002393000 dataset displayed the proteomic profiles of various organs in patients 115 The IPX0002393000 dataset displayed the proteomic profiles of various organs in patients<br>116 with COVID-19 (Table 1). An amount of 15 thyroid samples from the autonsy of infected 116 with COVID-19 (Table 1). An amount of 15 thyroid samples from the autopsy of infected 117 patients and 15 from non-infected patients were extracted. The IPX0001444000 dataset 117 patients and 15 from non-infected patients were extracted. The IPX0001444000 dataset<br>118 included 1161 samples of various thyroid diseases, including differentiated thyroid cancer 118 included 1161 samples of various thyroid diseases, including differentiated thyroid cancer<br>119 (DTC), benign thyroid diseases and normal thyroid tissues (NT). Two hundred and 119 (DTC), benign thyroid diseases and normal thyroid tissues (NT). Two hundred and<br>120 twenty-three samples of differentiated thyroid cancer or normal thyroid tissues in the 120 twenty-three samples of differentiated thyroid cancer or normal thyroid tissues in the discovery subgroup were collected for subsequent analysis. 121 discovery subgroup were collected for subsequent analysis.<br>122

#### 123 2.2 Identification of DEPs

124 Expression profiles were inputted into R project (v4.2.0). The clinical information was<br>125 collected from the two datasets for sample classification. Samples of irrelevant diseases were 125 collected from the two datasets for sample classification. Samples of irrelevant diseases were<br>126 excluded from the expression matrices. Missing data were imputed using the k-nearest 126 excluded from the expression matrices. Missing data were imputed using the k-nearest 127 neighbors algorithm in  $DMwR2$  package. Since technical replicates for each sample were set 127 neighbors algorithm in *DMwR2* package. Since technical replicates for each sample were set<br>128 and batch effects were minimized at the batch design level, the robust multi-array 128 and batch effects were minimized at the batch design level, the robust multi-array<br>129 normalization was not conducted so as not to eliminate the true difference (Sup figure 1). 129 normalization was not conducted so as not to eliminate the true difference (Sup figure 1).<br>130 UniProtKB AC/IDs were converted to general gene symbols via the online tool UniProt (29). 130 UniProtKB AC/IDs were converted to general gene symbols via the online tool UniProt (29).<br>131 When multiple protein IDs corresponded to one gene symbol, the medians were calculated. 131 When multiple protein IDs corresponded to one gene symbol, the medians were calculated.<br>132 The Bayesian method in the *limma* R package was used to identify the differentially 132 The Bayesian method in the *limma* R package was used to identify the differentially expressed proteins (DEPs) in two comparisons (COVID-19 *vs.* not infected, and DTC *vs.* NT). 133 expressed proteins (DEPs) in two comparisons (COVID-19 *vs.* not infected, and DTC *vs.* NT).<br>134 P-values were adjusted using the Benjamini-Hochberg method. Fold-changes (FCs) were <sup>134</sup>*P*-values were adjusted using the Benjamini-Hochberg method. Fold-changes (FCs) were

135 calculated with the false-discovery rate procedure. DTC-DEGs with  $|\log 2-\text{FC}| > 1$  and  $p < 0.01$ <br>136 were selected. COVID-19-DEGs were filtered according to the criteria  $|\log 2-\text{FC}| > 0.5$  and *p* 136 were selected. COVID-19-DEGs were filtered according to the criteria  $|\log 2-\text{FC}| > 0.5$  and *p*<br>137 < 0.01. The Venn diagram of DEGs was constructed with SangerBox (v3.0) (30) to identify 137  $\leq$  0.01. The Venn diagram of DEGs was constructed with SangerBox (v3.0) (30) to identify<br>138 the overlapping DEPs. Heatmaps were constructed to visualize the common DEPs in the two 138 the overlapping DEPs. Heatmaps were constructed to visualize the common DEPs in the two expression profiles. 139 expression profiles.<br>140

141 2.3 Gene ontology and pathway enrichment analysis

142 Gene ontology (GO) annotation and pathway analysis were performed with three online<br>143 tools, namely, DAVID (v2022q3), AmiGO (v2.5.17) and Reactome (v83) (31-33). The GO 143 tools, namely, DAVID (v2022q3), AmiGO (v2.5.17) and Reactome (v83) (31-33). The GO<br>144 enrichment analysis included three categories: biological process (BP), molecular function 144 enrichment analysis included three categories: biological process (BP), molecular function<br>145 (MF) and cellular component (CC). The results of GO enrichment were verified by the 145 (MF) and cellular component (CC). The results of GO enrichment were verified by the<br>146 AmiGO database. The Kvoto Encyclopedia of Genes and Genome (KEGG) was used to 146 AmiGO database. The Kyoto Encyclopedia of Genes and Genome (KEGG) was used to analyze the biological pathways in which the shared DEPs were mainly involved. The 147 analyze the biological pathways in which the shared DEPs were mainly involved. The 148 Reactome database was used to verify the results of KEGG. *P*-value <0.05 was deemed as the 148 Reactome database was used to verify the results of KEGG. *P*-value <0.05 was deemed as the 149 threshold for the GO enrichment analysis and the pathway analysis. The results were 149 threshold for the GO enrichment analysis and the pathway analysis. The results were visualized using bubble charts. 150 visualized using bubble charts.<br>151

#### 152 2.4 Construction of PPI network and identification of hub genes

153 The protein-protein interactions (PPIs) of shared DEPs were analyzed with an online tool,<br>154 STRING (v11.5) (34). PPIs with interaction scores >0.4 was considered significant. The 154 STRING (v11.5) (34). PPIs with interaction scores  $>0.4$  was considered significant. The results from STRING database were then imported into Cytoscape (v3.9.1) for visualization 155 results from STRING database were then imported into Cytoscape (v3.9.1) for visualization<br>156 of the PPIs. A plug-in software. CytoHubba (35), was used to identify the 20 hub genes with 156 of the PPIs. A plug-in software, CytoHubba (35), was used to identify the 20 hub genes with<br>157 eight algorithms (degree, edge percolated component, maximum neighborhood component, 157 eight algorithms (degree, edge percolated component, maximum neighborhood component,<br>158 maximal clique centrality, closeness, radiality, betweenness, and stress). The intersected hub 158 maximal clique centrality, closeness, radiality, betweenness, and stress). The intersected hub<br>159 senes were identified using the unset plot. GeneMania were utilized to construct the 159 genes were identified using the upset plot. GeneMania were utilized to construct the co-expression network of intersected hub genes and their related genes (36). 160 co-expression network of intersected hub genes and their related genes (36).<br>161 Receiver operator characteristics (ROC) curve and the area under the co

161 Receiver operator characteristics (ROC) curve and the area under the curve (AUC) were<br>162 utilized to evaluate the diagnostic accuracy of hub genes on COVID-19 and the DTC. 162 utilized to evaluate the diagnostic accuracy of hub genes on COVID-19 and the DTC.<br>163

#### 164 2.5 Associations between hub genes and diseases

165 The associations between the twelve hub genes and related diseases were analyzed using the<br>166 Comparative Toxicogenomics Database (CTD) (37). CTD is an innovative ecosystem that 166 Comparative Toxicogenomics Database (CTD) (37). CTD is an innovative ecosystem that 167 relates the toxicological information of genes to diseases. Diseases categorized as cancer, 167 relates the toxicological information of genes to diseases. Diseases categorized as cancer,<br>168 respiratory tract disease and viral disease were searched. Bar charts were produced to display 168 respiratory tract disease and viral disease were searched. Bar charts were produced to display<br>169 the associations between hub genes and COVID-19 and DTC. 169 the associations between hub genes and COVID-19 and DTC.<br>170

#### <sup>171</sup>**3 Results**

#### 172 3.1 Identification of DEPs in COVID-19 and DTC

173 A total of 18373 UniProt IDs were converted to 11615 and 6681 gene symbols for the two<br>174 datasets (IPX0001444000 and IPX0002393000), respectively. By comparing the thyroid 174 datasets (IPX0001444000 and IPX0002393000), respectively. By comparing the thyroid<br>175 samples from patients infected with COVID-19 and those not infected. 137 proteins were 175 samples from patients infected with COVID-19 and those not infected, 137 proteins were<br>176 confirmed as the COVID-19-DEPs. In addition, 1613 proteins were found to be DTC-DEPs 176 confirmed as the COVID-19-DEPs. In addition, 1613 proteins were found to be DTC-DEPs<br>177 by comparing DTC samples with NTs (Figure 2a&b). The Venn diagram depicted the shared 177 by comparing DTC samples with NTs (Figure 2a&b). The Venn diagram depicted the shared<br>178 DEPs of two comparisons. Forty-nine common DEPs were identified (Figure 2c & 178 DEPs of two comparisons. Forty-nine common DEPs were identified (Figure 2c & 179 Supplementary data). The expressions of common DEPs in two matrices were displayed with 179 Supplementary data). The expressions of common DEPs in two matrices were displayed with<br>180 heatmaps (Sup figure 2a&b). heatmaps (Sup figure  $2a\&b$ ).

181

#### 182 3.2 GO annotation and functional analysis of shared DEPs

183 GO annotations were performed with the DAVID database. A total of 64 GO terms with<br>184  $p$ -value <0.05 were revealed to be associated with the common DEPs (Figure 3a-c). The most 184 p-value <0.05 were revealed to be associated with the common DEPs (Figure 3a-c). The most enriched BPs were triglyceride-rich lipoprotein particle remodeling, negative regulation of 185 enriched BPs were triglyceride-rich lipoprotein particle remodeling, negative regulation of cholesterol transport and high-density lipoprotein particle clearance. The most enriched CCs 186 cholesterol transport and high-density lipoprotein particle clearance. The most enriched CCs<br>187 were focused on lipoproteins, including spherical high-density, very-low-density and 187 were focused on lipoproteins, including spherical high-density, very-low-density and<br>188 high-density lipoprotein particles. In addition, enzyme inhibitor activity, including lipase, 188 high-density lipoprotein particles. In addition, enzyme inhibitor activity, including lipase,<br>189 endopeptidase and cysteine-type endopeptidase, ranked top among the enriched MFs. The 189 endopeptidase and cysteine-type endopeptidase, ranked top among the enriched MFs. The fold enrichments (FEs) were > 30 for the MFs. BPs and CCs mentioned above. The above 190 fold enrichments (FEs) were  $>30$  for the MFs, BPs and CCs mentioned above. The above results were verified with AmiGO database (Supplementary data). 191 results were verified with AmiGO database (Supplementary data).<br>192 The results of Reactome pathway enrichment analysis were of

192 The results of Reactome pathway enrichment analysis were depicted in Figure 3d. The pathways that were most related to common DEPs were chylomicron assembly (FE=44.43). 193 pathways that were most related to common DEPs were chylomicron assembly (FE=44.43),<br>194 chylomicron remodeling (FE=36.59) and intrinsic pathway of fibrin clot formation 194 chylomicron remodeling (FE=36.59) and intrinsic pathway of fibrin clot formation<br>195 (FE=35.89). The pathway analysis from KEGG provided additional information 195 (FE=35.89). The pathway analysis from KEGG provided additional information 196 (Supplementary data). 196 (Supplementary data).<br>197

197

#### 198 3.3 PPI network construction and identification of hub genes

199 The PPI network included 38 nodes and 149 edges (Figure 4). Eleven common DEPs were<br>200 excluded due to no connectivity to other genes. Redder color indicated higher connectivity to 200 excluded due to no connectivity to other genes. Redder color indicated higher connectivity to<br>201 other genes. Of note, serpin family A member 1 (SERPINA1) was associated with 20 genes in 201 other genes. Of note, serpin family A member 1 (SERPINA1) was associated with 20 genes in the network. 202 the network.<br>203 The top tv

203 The top twenty hub gene lists generated by the eight algorithms in CytoHubba were<br>204 collected (Figure 5a). The intersection of the upset chart identified twelve final hub genes, 204 collected (Figure 5a). The intersection of the upset chart identified twelve final hub genes,<br>205 including AGT, AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, SERPINC1, including AGT, AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, SERPINC1,

206 TF and TTR. A complex gene interaction network was constructed with the GeneMania<br>207 database (Figure 5b). Co-expression contributed to the most interactions in the network 207 database (Figure 5b). Co-expression contributed to the most interactions in the network<br>208 (54.09%), followed by co-localizations and physical interactions (21.27% and 19.85%, 208 (54.09%), followed by co-localizations and physical interactions (21.27% and 19.85%, 209 respectively). The remodeling of protein-lipid complex, plasma lipoprotein particle and 209 respectively). The remodeling of protein-lipid complex, plasma lipoprotein particle and<br>210 rotein-containing complex were biological activities most likely associated with hub genes. 210 protein-containing complex were biological activities most likely associated with hub genes.<br>211 GO annotations and pathway enrichment analysis were conducted based on the twelve hu 211 GO annotations and pathway enrichment analysis were conducted based on the twelve hub<br>212 genes (Sup figure 3a&b). The top five GO terms that related to the hub genes were

212 genes (Sup figure 3a&b). The top five GO terms that related to the hub genes were<br>213 high-density lipoprotein particle clearance, spherical high-density lipoprotein particle. 213 high-density lipoprotein particle clearance, spherical high-density lipoprotein particle,<br>214 positive regulation of CoA-transferase activity, positive regulation of cholesterol esterification 214 positive regulation of CoA-transferase activity, positive regulation of cholesterol esterification<br>215 and high-density lipoprotein particle assembly. After excluding pathways which only one hub 215 and high-density lipoprotein particle assembly. After excluding pathways which only one hub<br>216 sene was involved. Reactome database revealed that intrinsic pathway of fibrin clot formation. 216 gene was involved, Reactome database revealed that intrinsic pathway of fibrin clot formation,<br>217 post-translational protein phosphorylation and regulation of insulin-like growth factor 217 post-translational protein phosphorylation and regulation of insulin-like growth factor<br>218 transport and uptake by insulin-like growth factor binding proteins were the most enriched 218 transport and uptake by insulin-like growth factor binding proteins were the most enriched<br>219 pathways related to hub genes. 219 pathways related to hub genes.<br>220

### 221 3.4 Diagnostic accuracy of hub genes

222 ROC curves were used to test the diagnostic performance of twelve hub genes (Figure 223 6a&b). In the COVID-19 dataset, apolipoprotein A2 (APOA2) and serpin family C member 1 223 6a&b). In the COVID-19 dataset, apolipoprotein A2 (APOA2) and serpin family C member 1<br>224 (SERPINC1) exhibited the highest diagnostic efficiency (AUC=1.00 for two genes), followed 224 (SERPINC1) exhibited the highest diagnostic efficiency (AUC=1.00 for two genes), followed<br>225 by complement C3 (C3) and inter-alpha-trypsin inhibitor heavy chain 2 (ITIH2) (AUC=0.96 225 by complement C3 (C3) and inter-alpha-trypsin inhibitor heavy chain 2 (ITIH2) (AUC=0.96<br>226 for two genes). In contrast, transferrin (TF) exhibited the best performance (AUC=0.80) in the 226 for two genes). In contrast, transferrin (TF) exhibited the best performance (AUC=0.80) in the 227 DTC dataset, followed by transthyretin (TTR, AUC=0.78), alpha 2-Heremans Schmidt 227 DTC dataset, followed by transthyretin (TTR, AUC=0.78), alpha 2-Heremans Schmidt 228 glvcoprotein (AHSG, AUC=0.78) and vitamin D binding protein (GC, AUC=0.77). 228 glycoprotein (AHSG, AUC=0.78) and vitamin D binding protein (GC, AUC=0.77).<br>229

230 3.5 Associations between hub genes and diseases

231 Ten among the twelve hub genes were shown to have potential interactions with COVID-19<br>232 (Figure 7). Notably, direct evidence has proved that angiotensinogen (AGT) participated in 232 (Figure 7). Notably, direct evidence has proved that angiotensinogen (AGT) participated in 233 the infection of SARS-CoV-2. Besides. C3 and kininogen 1 (KNG1) also had potential 233 the infection of SARS-CoV-2. Besides, C3 and kininogen 1 (KNG1) also had potential<br>234 interactions with COVID-19. The associations of hub genes and differentiated thyroid cancers 234 interactions with COVID-19. The associations of hub genes and differentiated thyroid cancers<br>235 were divided into three categories (PTC, FTC and thyroid neoplasms). Transthyretin (TTR), 235 were divided into three categories (PTC, FTC and thyroid neoplasms). Transthyretin (TTR),<br>236 C3, and apolipoprotein M (APOM) exhibited associations with thyroid cancers in all three 236 C3, and apolipoprotein M (APOM) exhibited associations with thyroid cancers in all three<br>237 categories. In addition. ITIH2 had the strongest connection (interference score=8.00) with 237 categories. In addition, ITIH2 had the strongest connection (interference score=8.00) with<br>238 FTC while TF connected with thyroid neoplasms (interference score=38.25). 238 FTC while TF connected with thyroid neoplasms (interference score=38.25).<br>239

#### <sup>240</sup>**4 Discussion**

241 In this study, twelve hub genes were identified from 49 common DEPs, including AGT,

<sup>239</sup> 

242 AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, SERPINC1, TF and TTR. GO<br>243 annotations and pathway enrichment analysis revealed several biological activities that might 243 annotations and pathway enrichment analysis revealed several biological activities that might<br>244 involve in the interaction of COVID-19 and DTC. Briefly, the *in vivo* transport and 244 involve in the interaction of COVID-19 and DTC. Briefly, the *in vivo* transport and metabolism of lipid and cholesterol are supposed to be the most likely common pathogenic 245 metabolism of lipid and cholesterol are supposed to be the most likely common pathogenic<br>246 mechanism in COVID-19 and DTC. In addition, vasodilation and coagulation process may 246 mechanism in COVID-19 and DTC. In addition, vasodilation and coagulation process may<br>247 also play roles, whereas chronic inflammation and immune response showed little effects. 247 also play roles, whereas chronic inflammation and immune response showed little effects.<br>248 The pathogenic effects of COVID-19 on thyroid gland have been gradually noticed since

248 The pathogenic effects of COVID-19 on thyroid gland have been gradually noticed since the<br>249 outbreak of the pandemic in Wuhan. In March 2020, a retrospective clinical study in Wuhan 249 outbreak of the pandemic in Wuhan. In March 2020, a retrospective clinical study in Wuhan<br>250 evaluated the clinical and laboratory data of 274 patient infected with the new coronavirus 250 evaluated the clinical and laboratory data of 274 patient infected with the new coronavirus<br>251 disease (38). In comparison with those who finally recovered from COVID-19, deceased 251 disease (38). In comparison with those who finally recovered from COVID-19, deceased<br>252 cases presented with lower levels of serum thyroxine and trijodothyronine. Confusingly, the 252 cases presented with lower levels of serum thyroxine and triiodothyronine. Confusingly, the<br>253 thyroid stimulation hormones were also decreased in these patients. Subsequent studies 253 thyroid stimulation hormones were also decreased in these patients. Subsequent studies<br>254 verified that ACE2 is the main host cell receptor for SARS-CoV-2 (39). Taken that ACE2 is 254 verified that ACE2 is the main host cell receptor for SARS-CoV-2 (39). Taken that ACE2 is<br>255 widely expressed in multiple organs, including thyroid and pituitary (25), we may 255 widely expressed in multiple organs, including thyroid and pituitary (25), we may<br>256 hypothesized that the hypothalamus-pituitary-thyroid axis is impaired during the infection. In 256 hypothesized that the hypothalamus-pituitary-thyroid axis is impaired during the infection. In<br>257 comparison with healthy controls, infected patients were more likely to develop 257 comparison with healthy controls, infected patients were more likely to develop 258 hyperthyroidism, as revealed by a retrospective study (40). Another study recruited 258 hyperthyroidism, as revealed by a retrospective study (40). Another study recruited 259 COVID-19 patients in the intensive care units (41). The incidence of subacute and atvoical 259 COVID-19 patients in the intensive care units (41). The incidence of subacute and atypical<br>260 thyroiditis was much higher in those with high intensity of care (10% vs. 0.5%). Besides. 260 thyroiditis was much higher in those with high intensity of care (10% *vs.* 0.5%). Besides,<br>261 Grave's disease could also be triggered by SARS-CoV-2 infection in patients with or without 261 Grave's disease could also be triggered by SARS-CoV-2 infection in patients with or without 262 a previous Grave's disease history (42, 43). Direct viral infection and hyperinflammatory state 262 a previous Grave's disease history (42, 43). Direct viral infection and hyperinflammatory state<br>263 by COVID-19 are both believed to induce thyroid autoimmune disorders. 263 by COVID-19 are both believed to induce thyroid autoimmune disorders.<br>264 Although numerous evidences have proven the damage of coronavirus of

264 Although numerous evidences have proven the damage of coronavirus on thyroid tissue, the<br>265 linkage between thyroid cancer and COVID-19 is unclear. Our previous study in Wuhan 265 linkage between thyroid cancer and COVID-19 is unclear. Our previous study in Wuhan showed that thyroid cancer behaviors were generally more aggressive compared to those 266 showed that thyroid cancer behaviors were generally more aggressive compared to those<br>267 before the pandemic (22). More cases with multiple lesions, extrathyroidal extension and 267 before the pandemic (22). More cases with multiple lesions, extrathyroidal extension and 268 lymph node metastasis were discovered. A multicenter cohort study in Los Angeles suggested 268 lymph node metastasis were discovered. A multicenter cohort study in Los Angeles suggested<br>269 that comorbidities and old age are hazard factors for patients diagnosed with both thyroid 269 that comorbidities and old age are hazard factors for patients diagnosed with both thyroid<br>270 cancer and COVID-19 (21). Another nationwide study evaluated the COVID-19 outcomes 270 cancer and COVID-19 (21). Another nationwide study evaluated the COVID-19 outcomes<br>271 and mortality in thyroid cancer patients with COVID-19 infection (44). No elevation in 271 and mortality in thyroid cancer patients with COVID-19 infection (44). No elevation in<br>272 mortality and morbidity was revealed. The conclusions were verified by a multicenter cohort 272 mortality and morbidity was revealed. The conclusions were verified by a multicenter cohort<br>273 study conducted in South Korea (45). Nevertheless, considering the fact that a small 273 study conducted in South Korea (45). Nevertheless, considering the fact that a small proportion of patients receive tyrosine kinase inhibitor therapy or have distant metastasis, it is 274 proportion of patients receive tyrosine kinase inhibitor therapy or have distant metastasis, it is<br>275 easonable to anticipate that these patients are at high risk for complications of COVID-19.

275 reasonable to anticipate that these patients are at high risk for complications of COVID-19.<br>276 Among the twelve hub genes identified. AGT is the gene most related to COVID-19. A 276 Among the twelve hub genes identified, AGT is the gene most related to COVID-19. AGT<br>277 gene encodes for the angiotensinogen precursor, which is quickly converted to angiotensin I 277 gene encodes for the angiotensinogen precursor, which is quickly converted to angiotensin I<br>278 with the regulation of blood pressure and renin. Two retrospective studies drew the same 278 with the regulation of blood pressure and renin. Two retrospective studies drew the same<br>279 conclusion that AGT rs699 C>T single-nucleotide polymorphism could increase the risk and 279 conclusion that AGT rs699 C>T single-nucleotide polymorphism could increase the risk and<br>280 severity of COVID-19 (46, 47). Another study collected serum samples from 45 infected 280 severity of COVID-19 (46, 47). Another study collected serum samples from 45 infected<br>281 patients and 34 controls (48). Proteomic analysis revealed that AGT was elevated in almost all 281 patients and 34 controls (48). Proteomic analysis revealed that AGT was elevated in almost all<br>282 infected patients and its serum concentration was strongly indicative of disease severity. 282 infected patients and its serum concentration was strongly indicative of disease severity.<br>283 Taken that ACE2 is the key factor in the internalization of SARS-CoV-2, the 283 Taken that ACE2 is the key factor in the internalization of SARS-CoV-2, the renin-angiotensin-aldosterone (RAS) system is supposed to over-activate in response to 284 renin-angiotensin-aldosterone (RAS) system is supposed to over-activate in response to<br>285 COVID-19. The RAS system was less studied in thyroid carcinomas. A clinical study <sup>285</sup>COVID-19. The RAS system was less studied in thyroid carcinomas. A clinical study

286 revealed a significantly increased expression of ACE2 in cancer tissues in comparison with<br>287 benign nodules (49). The result suggested that the RAS system might involve in tumor 287 benign nodules (49). The result suggested that the RAS system might involve in tumor<br>288 progression, as supported in previous basic research (50). However, direct and solid evidences 288 progression, as supported in previous basic research (50). However, direct and solid evidences<br>289 are lacking in the relationship between AGT and thyroid cancers. 289 are lacking in the relationship between AGT and thyroid cancers.<br>290 KNG1 is an essential factor in the kallikrein-kinin system and

290 KNG1 is an essential factor in the kallikrein-kinin system and plays an important role in<br>291 blood coagulation. The over expression of KNG1 could inhibit proliferation and induce 291 blood coagulation. The over expression of KNG1 could inhibit proliferation and induce<br>292 apoptosis of glioma cells (51). Its anticancer mechanisms include the induction of G1 phase 292 apoptosis of glioma cells (51). Its anticancer mechanisms include the induction of G1 phase<br>293 cell cycle, the activation of caspase 3 and 9 and the inhibition of vascular endothelial growth 293 cell cycle, the activation of caspase 3 and 9 and the inhibition of vascular endothelial growth<br>294 factor expression. Of interest, the expression of KNG1 was increased in colorectal cancers (52, 294 factor expression. Of interest, the expression of KNG1 was increased in colorectal cancers (52, 295 53). The phenomenon could be explained by the compensative effect of cancer tissues. In 295 53). The phenomenon could be explained by the compensative effect of cancer tissues. In<br>296 patients with COVID-19. KNG1 was shown to be upregulated in circulation together with 296 patients with COVID-19, KNG1 was shown to be upregulated in circulation together with<br>297 other regulators of coagulation (plasminogen, fibronectin 1, etc.) (54), suggesting that 297 other regulators of coagulation (plasminogen, fibronectin 1, etc.) (54), suggesting that coagulation dysfunction might occur. 298 coagulation dysfunction might occur.<br>299 Linid and cholesterol metabolism an

299 Lipid and cholesterol metabolism and transport are biological processes most likely involved<br>300 in the common pathogenic mechanism of COVID-19 and DTC. Schmelter *et al.* collected 482 300 in the common pathogenic mechanism of COVID-19 and DTC. Schmelter *et al.* collected 482<br>301 serum samples from infected patients and healthy volunteers and tested the serum lipid profile. 301 serum samples from infected patients and healthy volunteers and tested the serum lipid profile.<br>302 They discovered that very-low-density lipoprotein, intermediate-density lipoprotein particles 302 They discovered that very-low-density lipoprotein, intermediate-density lipoprotein particles<br>303 and associated apolipoprotein B were significantly elevated in patients with SARS-CoV-2 303 and associated apolipoprotein B were significantly elevated in patients with SARS-CoV-2<br>304 infection, whereas cholesterol and APOA2 were decreased (55). In another study using the 304 infection, whereas cholesterol and APOA2 were decreased (55). In another study using the<br>305 proteomic approach with 41 patients. APOM in high-density lipoprotein was inversely 305 proteomic approach with 41 patients, APOM in high-density lipoprotein was inversely<br>306 associated with the odds of death due to COVID-19 complications (56). Since numerous 306 associated with the odds of death due to COVID-19 complications (56). Since numerous<br>307 studies have reported dyslipidemia due to COVID-19, recent researches uncovered the 307 studies have reported dyslipidemia due to COVID-19, recent researches uncovered the<br>308 underlying mechanisms. When SARS-CoV-2 enters the host cell via the receptor ACE2. 308 underlying mechanisms. When SARS-CoV-2 enters the host cell via the receptor ACE2,<br>309 cholesterol is essential for the formation of syncytia (57). This might help to explain the 309 cholesterol is essential for the formation of syncytia (57). This might help to explain the<br>310 success of lipid apheresis as the treatment for patients with long-COVID syndromes (58). 310 success of lipid apheresis as the treatment for patients with long-COVID syndromes (58).<br>311 Previous studies have proved that dyslipidemia, especially hyperlipidemia and 311 Previous studies have proved that dyslipidemia, especially hyperlipidemia<br>312 hypercholesterolemia, could increase the risk of various cancers (59, 60). Excess lipid 312 hypercholesterolemia, could increase the risk of various cancers (59, 60). Excess lipid and<br>313 cholesterol would increase intracellular oxidative stress and consequently promote 313 cholesterol would increase intracellular oxidative stress and consequently promote<br>314 carcinogenesis and aggressiveness (61). Evidence has shown that linid metabolism was 314 carcinogenesis and aggressiveness (61). Evidence has shown that lipid metabolism was<br>315 impaired in those individuals with long-COVID-19 (62), we could postulate that dyslipidemia 315 impaired in those individuals with long-COVID-19 (62), we could postulate that dyslipidemia<br>316 due to post-acute sequelae of COVID-19 might elevate the risk of thyroid cancer in a long 316 due to post-acute sequelae of COVID-19 might elevate the risk of thyroid cancer in a long<br>317 term. 317 term.<br>318 The

318 The associations between other hub genes and COVID-19 and DTC were also studied. C3<br>319 encodes for complement component 3. The complement system can be activated by several 319 encodes for complement component 3. The complement system can be activated by several<br>320 different mechanisms in acute inflammation and malignancies. The clinical studies of C3 in 320 different mechanisms in acute inflammation and malignancies. The clinical studies of C3 in<br>321 COVID-19 are controversial. Some reports favored that decreased C3 levels were associated 321 COVID-19 are controversial. Some reports favored that decreased C3 levels were associated<br>322 with the disease severity (63, 64), while another research found no statistical significance (65). 322 with the disease severity (63, 64), while another research found no statistical significance (65).<br>323 A clinical study evaluated the proteomic profile in fine needle aspiration biopsy (66). C3 323 A clinical study evaluated the proteomic profile in fine needle aspiration biopsy (66). C3<br>324 expression was discovered to decrease in PTC tissues, which could activate the downstream 324 expression was discovered to decrease in PTC tissues, which could activate the downstream<br>325 complement system and exert a compensative anticancer effect. Similar to this article. GC 325 complement system and exert a compensative anticancer effect. Similar to this article, GC<br>326 expression was also altered in our study. A previous research observed a decreased GC in 326 expression was also altered in our study. A previous research observed a decreased GC in<br>327 PTC tissue was related to enhanced tumor proliferation and migration (67). The link between 327 PTC tissue was related to enhanced tumor proliferation and migration (67). The link between<br>328 COVID-19 and GC is unclear currently. A commentary postulated that GC might play a role 328 COVID-19 and GC is unclear currently. A commentary postulated that GC might play a role<br>329 in vitamin D deficiency in infected patients (68). Besides. TF, an iron-related serum protein in vitamin D deficiency in infected patients (68). Besides, TF, an iron-related serum protein

330 associated with chronic inflammation, was proved to be indicative of the severity and<br>331 coasulative state in COVID-19 patients (69-71). However, the association between TF and 331 coagulative state in COVID-19 patients (69-71). However, the association between TF and<br>332 DTC, if exists, was unknown. Of the rest five hub genes, the levels of AHSG, ITIH2 and 332 DTC, if exists, was unknown. Of the rest five hub genes, the levels of AHSG, ITIH2 and<br>333 SERPINA1 were found to be the predictors of severity in patients with SARS-CoV-2 333 SERPINA1 were found to be the predictors of severity in patients with SARS-CoV-2<br>334 infection (72-74). Besides, the expressions of AHSG, SERPINA1 and TTR were altered in 334 infection (72-74). Besides, the expressions of AHSG, SERPINA1 and TTR were altered in<br>335 PTCs (75-77). Of note, the above researches utilized omics methods to evaluate the 335 PTCs (75-77). Of note, the above researches utilized omics methods to evaluate the expression profiles but the underlying mechanisms between molecules and diseases were not 336 expression profiles but the underlying mechanisms between molecules and diseases were not<br>337 explored. The roles of SERPINC1 in COVID-19 and thyroid cancer have not been studied. 337 explored. The roles of SERPINC1 in COVID-19 and thyroid cancer have not been studied.<br>338 One letter published in Sept 2022 conducted a bioinformatic analysis similar to our studied.

338 One letter published in Sept 2022 conducted a bioinformatic analysis similar to our study<br>339 (78). In this study, a database from iProx was analyzed for the identification of DEPs. The 339 (78). In this study, a database from iProx was analyzed for the identification of DEPs. The transcription profiles of thyroid cancers and normal controls were downloaded from the data 340 transcription profiles of thyroid cancers and normal controls were downloaded from the data<br>341 from the Cancer Genome Atlas (TCGA) database. Using a different algorithm and criteria 341 from the Cancer Genome Atlas (TCGA) database. Using a different algorithm and criteria<br>342  $(n<0.05, \log 2|FC|>1)$ , this research identified ten more DEPs for COVID-19-infected thyroid  $\frac{342}{134}$  (*p*<0.05, log2|FC|>1), this research identified ten more DEPs for COVID-19-infected thyroid<br> $\frac{343}{134}$  tissues (137 in our study and 147 in this study). Besides, 31 differentially expressed genes 343 tissues (137 in our study and 147 in this study). Besides, 31 differentially expressed genes<br>344 were determined with 568 TCGA samples. However, only one common gene/protein 344 were determined with 568 TCGA samples. However, only one common gene/protein<br>345 (coagulation factor XII) was identified with the Venn diagram. This pilot research has some 345 (coagulation factor XII) was identified with the Venn diagram. This pilot research has some<br>346 defects in the study design. First, samples in TCGA databases were collected from different 346 defects in the study design. First, samples in TCGA databases were collected from different<br>347 sources and batches. The batch effects between arravs were not normalized before analysis. 347 sources and batches. The batch effects between arrays were not normalized before analysis.<br>348 Second. differential expression analysis was conducted on both mRNA and protein levels. 348 Second, differential expression analysis was conducted on both mRNA and protein levels.<br>349 Altered mRNA expressions do not certainly indicate the changes of translation, and vice versa 349 Altered mRNA expressions do not certainly indicate the changes of translation, and vice versa.<br>350 Finally, the GO annotations and pathway enrichment analysis were not conducted, which 350 Finally, the GO annotations and pathway enrichment analysis were not conducted, which<br>351 limited the generalization of conclusions. 351 limited the generalization of conclusions.<br>352 There are some limitations in our study

352 There are some limitations in our study. First, due to the lack of patients with concomitant the study there is a study were not validated in human samples. 353 thyroid cancer and COVID-19, the results of our study were not validated in human samples.<br>354 Second, we identified some novel molecules associated with SARS-CoV-2 infection or DTC, 354 Second, we identified some novel molecules associated with SARS-CoV-2 infection or DTC,<br>355 the underlying mechanisms were not evaluated with *in vitro* or *in vivo* experiments. Besides, 355 the underlying mechanisms were not evaluated with *in vitro* or *in vivo* experiments. Besides,<br>356 only 30 samples were extracted and analyzed in the matrix of COVID-19. The sample size 356 only 30 samples were extracted and analyzed in the matrix of COVID-19. The sample size<br>357 was relatively small. 357 was relatively small.<br>358 In conclusion, our

358 In conclusion, our study identified twelve hub genes from 49 common DEPs. GO<br>359 annotations and pathway enrichment analysis focused on lipid and cholesterol metabolism 359 annotations and pathway enrichment analysis focused on lipid and cholesterol metabolism<br>360 and transport, followed by vasodilation and coagulation process. The common pathogenic 360 and transport, followed by vasodilation and coagulation process. The common pathogenic<br>361 mechanisms suggest the infection of SARS-CoV-2 might exert adverse effects on patients 361 mechanisms suggest the infection of SARS-CoV-2 might exert adverse effects on patients<br>362 with DTCs. Further clinical and basic researches are needed to verify our conclusions. 362 with DTCs. Further clinical and basic researches are needed to verify our conclusions.<br>363

#### <sup>365</sup>**Abbreviations**

366 ACE2, angiotensin-converting enzyme 2; AGT, angiotensinogen; AHSG, alpha 2-Heremans<br>367 Schmidt glycoprotein; APOA2, apolipoprotein A2; APOM, apolipoprotein M; AUC, the area 367 Schmidt glycoprotein; APOA2, apolipoprotein A2; APOM, apolipoprotein M; AUC, the area<br>368 under the curve: BP, biological process: C3, complement C3: CC, cellular component: 368 under the curve; BP, biological process; C3, complement C3; CC, cellular component; 369 COIVD-19, coronavirus disease 2019; CTD, Comparative Toxicogenomics Database; DEP, 369 COIVD-19, coronavirus disease 2019; CTD, Comparative Toxicogenomics Database; DEP,<br>370 differentially expressed protein: DTC, differentiated thyroid cancer: EBV, Epstein-Barr virus: 370 differentially expressed protein; DTC, differentiated thyroid cancer; EBV, Epstein-Barr virus;<br>371 FC, fold change: FE, fold enrichment: FTC, follicular thyroid cancer; GC, vitamin D binding 371 FC, fold change; FE, fold enrichment; FTC, follicular thyroid cancer; GC, vitamin D binding<br>372 protein; GO, Gene Ontology; ITIH2, inter-alpha-trypsin inhibitor heavy chain 2; KEGG, 372 protein; GO, Gene Ontology; ITIH2, inter-alpha-trypsin inhibitor heavy chain 2; KEGG, 373 Kvoto Encyclopedia of Genes and Genome: KNG1, kininogen 1: MF, molecular function: NT. 373 Kyoto Encyclopedia of Genes and Genome; KNG1, kininogen 1; MF, molecular function; NT,<br>374 normal thyroid tissues: PPI, protein-protein interaction: PTC, papillary thyroid cancer: RAS, 374 normal thyroid tissues; PPI, protein-protein interaction; PTC, papillary thyroid cancer; RAS, renin-angiotensin-aldosterone; ROC, receiver operator characteristics; SARS-CoV-2, severe 375 renin-angiotensin-aldosterone; ROC, receiver operator characteristics; SARS-CoV-2, severe<br>376 acute respiratory syndrome coronavirus 2; SERPINA1, serpin family A member 1; 376 acute respiratory syndrome coronavirus 2; SERPINA1, serpin family A member 1;<br>377 SERPINC1, serpin family C member 1: TCGA, the Cancer Genome Atlas: TF transferrin: 377 SERPINC1, serpin family C member 1; TCGA, the Cancer Genome Atlas; TF, transferrin; 378 TriC/CCT, T-complex protein 1 ring complex/chaperonin-containing T-complex protein 1; 378 TriC/CCT, T-complex protein 1 ring complex/chaperonin-containing T-complex protein 1;<br>379 TTR transthvretin: 379 TTR, transthyretin;<br>380

#### <sup>381</sup>**Disclosures**

- 382 Conflicts of interest
- 383 The authors declare no conflict of interest.<br>384
- 
- 385 Authors contribution
- 386 Conceptualization: HQ. Liu & C. Chen<br>387 Methodology: HQ. Liu, JX. Wang & C.
- 387 Methodology: HQ. Liu, JX. Wang & C. Chen<br>388 Formal analysis: HO. Liu, JX. Wang & D. Yan
- 388 Formal analysis: HQ. Liu, JX. Wang & D. Yang<br>389 Investigation: HQ. Liu, JX. Wang & D. Yang
- 389 Investigation: HQ. Liu, JX. Wang & D. Yang<br>390 Writing original draft preparation: HO. Liu
- 390 Writing original draft preparation: HQ. Liu & JX. Wang<br>391 Writing review and editing: D. Yang & C. Chen
- 391 Writing review and editing: D. Yang & C. Chen<br>392 Supervision: C. Chen
- 392 Supervision: C. Chen<br>393 Funding acquisition: 0
- 393 Funding acquisition: C. Chen<br>394
- 
- 395 Acknowledgments
- 396 We wish to thank researchers who provide the two proteomic profiles.<br>397
- 

398 Funding

399 This research was supported by the grants from Beijing Xisike Clinical Oncology Research<br>400 Foundation (Y-SY201901-0189), the Fundamental Research Funds for the Central 400 Foundation (Y-SY201901-0189), the Fundamental Research Funds for the Central<br>401 Universities (2042019kf0229), the Science and Technology Maior Project of Hubei Province 401 Universities (2042019kf0229), the Science and Technology Major Project of Hubei Province<br>402 (Next-Generation AI Technologies) (2019AEA170). 402 (Next-Generation AI Technologies) (2019AEA170).<br>403

404 Data availability

405 The two proteomic profiles can be downloaded from iProx database (IPX0001444000  $\&$  406 IPX0002393000). Supplementary figures and data files were deposited in Mendeley database 106 IPX0002393000). Supplementary figures and data files were deposited in Mendeley database<br>107 (DOI: 10.17632/5cg2dmz5nb.2). <sup>407</sup>(DOI: 10.17632/5cg2dmz5nb.2).

#### <sup>409</sup>**References**

- 410 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Ca-a Cancer Journal for Clinicians. 2022:72(1):7-33.
- 411 Clinicians. 2022;72(1):7-33.<br>412 2. Guav B. Johnson-Obas 412 2. Guay B, Johnson-Obaseki S, McDonald JT, Connell C, Corsten M. Incidence of Differentiated<br>413 Thyroid Cancer by Socioeconomic Status and Urban Residence: Canada 1991-2006. Thyroid.
- 413 Thyroid Cancer by Socioeconomic Status and Urban Residence: Canada 1991-2006. Thyroid.<br>414 2014:24(3):552-5. 414 2014;24(3):552-5.<br>415 3. Yan KL, Li
- 415 3. Yan KL, Li S, Tseng C-H, Kim J, Nguyen DT, Dawood NB, et al. Rising Incidence and 16 Incidence-Based Mortality of Thyroid Cancer in California. 2000-2017. Journal of Clinical 416 Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017. Journal of Clinical 417 Endocrinology & Metabolism. 2020:105(6):1770-7. 417 Endocrinology & Metabolism. 2020;105(6):1770-7.<br>418 4. Baneriee M, Wiebel JL, Guo C, Gay B, H
- 418 4. Banerjee M, Wiebel JL, Guo C, Gay B, Haymart MR. Use of imaging tests after primary<br>419 treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating 419 treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating<br>420 death and recurrence British Medical Journal 2016:354:i3839 420 death and recurrence. British Medical Journal. 2016;354:i3839.<br>421 5. Davies L. Hoang JK. Thyroid cancer in the USA: current t

421 5. Davies L, Hoang JK. Thyroid cancer in the USA: current trends and outstanding questions. Lancet 22 Diabetes & Endocrinology. 2021:9(1):11-2. 422 Diabetes & Endocrinology. 2021;9(1):11-2.<br>423 6. Li O. Li X. Sun J. Di W. Zhang

- 423 6. Li Q, Li X, Sun J, Di W, Zhang L. The relationship between the thyroid carcinoma and epstein-barr virus infection. Chinese Journal of Experimental Surgery. 2014;31(3):627-9. 424 epstein-barr virus infection. Chinese Journal of Experimental Surgery. 2014;31(3):627-9.<br>425 7. Moghoofei M. Mostafaei S. Nesaei A. Etemadi A. Nahand JS. Mirzaei H. et al. Eps
- 425 7. Moghoofei M, Mostafaei S, Nesaei A, Etemadi A, Nahand JS, Mirzaei H, et al. Epstein-Barr virus<br>426 and thyroid cancer: The role of viral expressed proteins. Journal of Cellular Physiology. 426 and thyroid cancer: The role of viral expressed proteins. Journal of Cellular Physiology.<br>427 2019:234(4):3790-9. 427 2019;234(4):3790-9.<br>428 8. Antonelli A. F
- 428 8. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, et al. Thyroid cancer in <br>429 HCV-related chronic hepatitis patients: A case-control study. Thyroid. 2007:17(5):447-51. 429 HCV-related chronic hepatitis patients: A case-control study. Thyroid. 2007;17(5):447-51.<br>430 9. An J. Kim JW. Shim JH. Han S. Yu CS. Choe J. et al. Chronic hepatitis B
- 430 9. An J, Kim JW, Shim JH, Han S, Yu CS, Choe J, et al. Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study. Plos One. 431 non-hepatocellular cancers: A hospital registry-based, case-control 432 2018:13(3):e0193232. 432 2018;13(3):e0193232.<br>433 10. Hong CY. Sinn I
- 433 10. Hong CY, Sinn DH, Kang D, Paik SW, Guallar E, Cho J, et al. Incidence of extrahepatic cancers<br>434 among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. Journal of 434 among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. Journal of 435 Viral Hepatitis. 2020:27(9):896-903. 435 Viral Hepatitis. 2020;27(9):896-903.<br>436 11. Wang JH. Zhang WP. Liu HX.
- 436 11. Wang JH, Zhang WP, Liu HX, Wang D, Li YF, Wang WQ, et al. Detection of human parvovirus 437 B19 in papillary thyroid carcinoma. British Journal of Cancer. 2008:98(3):611-8. 437 B19 in papillary thyroid carcinoma. British Journal of Cancer. 2008;98(3):611-8.<br>438 12 Adamson LA Fowler LI Clare-Salzler MI Hobbs IA Parvovirus B19 In
- 12. Adamson LA, Fowler LJ, Clare-Salzler MJ, Hobbs JA. Parvovirus B19 Infection in Hashimoto's<br>139 Thyroiditis. Papillary Thyroid Carcinoma. and Anaplastic Thyroid Carcinoma. Thyroid. 439 Thyroiditis, Papillary Thyroid Carcinoma, and Anaplastic Thyroid Carcinoma. Thyroid.<br>440 2011:21(4):411-7. 440 2011;21(4):411-7.<br>441 13. Tsai JH. Tsa
- 441 13. Tsai JH, Tsai CH, Cheng MH, Lin SJ, Xu FL, Yang CC. Association of viral factors with<br>442 non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid 142 non-familial breast cancer in Taiwan by comparison with non-cancerous, fibroadenoma, and thyroid<br>143 tumor tissues. Journal of Medical Virology. 2005:75(2):276-81. 443 tumor tissues. Journal of Medical Virology. 2005;75(2):276-81.<br>444 14. Arisawa K, Soda M, Akahoshi M, Fujiwara S, Uemur
- 444 14. Arisawa K, Soda M, Akahoshi M, Fujiwara S, Uemura H, Hiyoshi M, et al. Human T-cell<br>445 lymphotropic virus type-1 infection and risk of cancer: 15.4 year longitudinal study among atomic 145 lymphotropic virus type-1 infection and risk of cancer: 15.4 year longitudinal study among atomic<br>146 bomb survivors in Nagasaki, Japan. Cancer Science. 2006:97(6):535-9.
- 446 bomb survivors in Nagasaki, Japan. Cancer Science. 2006;97(6):535-9.<br>447 15 Hobbs JA Adamson-Small LA Parvovinus and Thyroid Ca 447 15. Hobbs JA, Adamson-Small LA. Parvovirus and Thyroid Cancer. Seminars in Oncology.<br>448 2015:42(2):304-8. 448 2015;42(2):304-8.<br>449 16. Worldometer.
- 449 16. Worldometer. Countries where COVID-19 has spread 2022 [Available from: 450 https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread/?rel=outbound.<br>13

- 451 17. Chen K, Jiang S, Hu A. Research progress on the mechanism of multiple organ dysfunction in<br>452 patients with COVID-19. Chinese Journal of Clinical Infectious Diseases 2021:14(2):102-6.
- 452 patients with COVID-19. Chinese Journal of Clinical Infectious Diseases. 2021;14(2):102-6.<br>453 18. Mitsuyama K, Tsuruta K, Takedatsu H, Yoshioka S, Morita M, Niwa M, et al. Clinica
- 453 18. Mitsuyama K, Tsuruta K, Takedatsu H, Yoshioka S, Morita M, Niwa M, et al. Clinical Features<br>454 and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19. Journal of Clinical Medicine.
- and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19. Journal of Clinical Medicine.<br>455 2020:9(11):3630. 455 2020;9(11):3630.<br>456 19. Chegini R.
- 456 19. Chegini R, Mojtahedi Z, Lakkakula BVKS, Pezeshgi A, Niazi S, Nasri H. COVID-19 and the 457 kidney: mechanisms of tubular injury by SARS-CoV-2. Journal of Renal Injury Prevention. 457 kidney; mechanisms of tubular injury by SARS-CoV-2. Journal of Renal Injury Prevention.<br>458 2021:10(1):e08.
- 458 2021;10(1):e08.<br>459 20. Yi J, Miao 459 20. Yi J, Miao J, Zuo Q, Owusu F, Dong Q, Lin P, et al. COVID-19 pandemic: A multidisciplinary<br>460 perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological 460 perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. Frontiers in Immunology, 2022:13:978619.
- 461 responses. Frontiers in Immunology. 2022;13:978619.<br>462 21. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim l 462 21. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, et al. COVID-19 Outcomes<br>463 of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocrine 463 of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocrine<br>464 Practice. 2021;27(2):90-4.
- 464 Practice. 2021;27(2):90-4.<br>465 22. Liu HO, Zhan L, Gu 465 22. Liu HQ, Zhan L, Guo LT, Yu XZ, Li LR, Feng HF, et al. More Aggressive Cancer Behaviour in<br>466 Thyroid Cancer Patients in the Post-COVID-19 Pandemic Era: A Retrospective Study. International
- 466 Thyroid Cancer Patients in the Post-COVID-19 Pandemic Era: A Retrospective Study. International 467 Journal of General Medicine. 2021:14:7197-206.
- 467 Journal of General Medicine. 2021;14:7197-206.<br>468 23. Duntas LH, Jonklaas J. COVID-19 and Th 468 23. Duntas LH, Jonklaas J. COVID-19 and Thyroid Diseases: A Bidirectional Impact. Journal of the 469 Endocrine Society. 2021:5(8):bvab076. 469 Endocrine Society. 2021;5(8):bvab076.<br>470 24. Scappaticcio L. Pitoja F. Esposito
- 470 24. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Reviews in endocrine & metabolic disorders. 2021;22(4):803-15. 471 gland: an update. Reviews in endocrine & metabolic disorders. 2021;22(4):803-15.<br>472 25. Li M-Y, Li L. Zhang Y. Wang X-S. Expression of the SARS-CoV-2 cell recently
- 472 25. Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a<br>473 wide variety of human tissues. Infectious Diseases of Poverty. 2020:9(1):45.
- 473 wide variety of human tissues. Infectious Diseases of Poverty. 2020;9(1):45.<br>474 26. Ma J. Chen T. Wu S. Yang C. Bai M. Shu K. et al. iProX: an inte 474 26. Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource.<br>475 Nucleic Acids Research. 2019:47(D1):D1211-D7.
- 475 Nucleic Acids Research. 2019;47(D1):D1211-D7.<br>476 27. Nie X. Oian L. Sun R. Huang B. Dong X. 476 27. Nie X, Qian L, Sun R, Huang B, Dong X, Xiao Q, et al. Multi-organ proteomic landscape of 477 COVID-19 autopsies. Cell. 2021;184(3):775-91.e14. 477 COVID-19 autopsies. Cell. 2021;184(3):775-91.e14.<br>478 28. Sun Y. Selvaraian S. Zang Z. Liu W. Zhu Y
- 478 28. Sun Y, Selvarajan S, Zang Z, Liu W, Zhu Y, Zhang H, et al. Artificial intelligence defines<br>479 protein-based classification of thyroid nodules. Cell Discovery, 2022;8(1):85.
- 479 protein-based classification of thyroid nodules. Cell Discovery. 2022;8(1):85.<br>480 29. Bateman A, Martin M-J, Orchard S, Magrane M, Agivetova R, Ahm 480 29. Bateman A, Martin M-J, Orchard S, Magrane M, Agivetova R, Ahmad S, et al. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Research. 2021:49(D1):D480-D9. 481 universal protein knowledgebase in 2021. Nucleic Acids Research. 2021;49(D1):D480-D9.<br>482 30. Shen W. Song Z. Zhong X. Huang M. Shen D. Gao P. et al. Sangerbox: A con
- 482 30. Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P, et al. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022:1(3):e36.
- 483 interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1(3):e36.<br>484 31. Carbon S. Ireland A. Mungall C.J. Shu S. Marshall B. Lewis S. AmiGO: online
- 484 31. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S. AmiGO: online access to ontology and annotation data. Bioinformatics. 2009:25(2):288-9.
- 485 and annotation data. Bioinformatics. 2009;25(2):288-9.<br>486 32. Huang DW, Sherman BT, Lempicki RA. System
- 486 32. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists 487 using DAVID bioinformatics resources. Nature Protocols. 2009:4(1):44-57.
- 487 using DAVID bioinformatics resources. Nature Protocols. 2009;4(1):44-57.<br>488 33. Gillespie M. Jassal B. Stephan R. Milacic M. Rothfels K. Senff-Rib 488 33. Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome<br>489 pathway knowledgebase 2022. Nucleic Acids Research. 2022;50(D1):D687-D92.
- 489 pathway knowledgebase 2022. Nucleic Acids Research. 2022;50(D1):D687-D92.<br>490 34. Szklarczyk D. Gable AL. Nastou KC. Lyon D. Kirsch R. Pyysalo S. et al. 1
- 490 34. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database<br>491 in 2021: customizable protein-protein networks, and functional characterization of user-uploaded
- 491 in 2021: customizable protein-protein networks, and functional characterization of user-uploaded<br>492 gene/measurement sets. Nucleic Acids Research. 2021;49(D1):D605-D12.
- 492 gene/measurement sets. Nucleic Acids Research. 2021;49(D1):D605-D12.<br>493 35. Chin C-H. Chen S-H. Wu H-H. Ho C-W. Ko M-T. Lin C-Y. cvtoHu
- 493 35. Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. Bmc Systems Biology. 2014:8:S11.
- and sub-networks from complex interactome. Bmc Systems Biology. 2014;8:S11.

495 36. Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD, et al. GeneMANIA update<br>496 2018. Nucleic Acids Research. 2018:46(W1):W60-W4.

- 496 2018. Nucleic Acids Research. 2018;46(W1):W60-W4.<br>497 37. Davis AP, Grondin CJ, Johnson RJ, Sciaky D, 497 37. Davis AP, Grondin CJ, Johnson RJ, Sciaky D, Wiegers J, Wiegers TC, et al. Comparative 498 Toxicogenomics Database (CTD): update 2021. Nucleic Acids Research. 2021:49(D1):D1138-D43.
- 498 Toxicogenomics Database (CTD): update 2021. Nucleic Acids Research. 2021;49(D1):D1138-D43.<br>499 38. Chen T. Wu D. Chen H. Yan W. Yang D. Chen G. et al. Clinical characteristics of 113 decea 499 38. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased<br>500 patients with coronavirus disease 2019: retrospective study. British Medical Journal. 2020:368:m1091.
- 500 patients with coronavirus disease 2019: retrospective study. British Medical Journal. 2020;368:m1091.<br>501 39. Lu R. Zhao X. Li J. Niu P. Yang B. Wu H. et al. Genomic characterisation and epidemiology of
- 501 39. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 502 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet.
- 502 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet.<br>503 2020:395(10224):565-74. 503 2020;395(10224):565-74.<br>504 40. Lania A. Sandri M'
- 504 40. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G, et al. Thyrotoxicosis in<br>505 patients with COVID-19: the THYRCOV study. European Journal of Endocrinology. 505 patients with COVID-19: the THYRCOV study. European Journal of Endocrinology.<br>506 2020;183(4):381-7. 506 2020;183(4):381-7.<br>507 41. Muller I. Ca
- 507 41. Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, et al.<br>508 SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes & Endocrinology. 2020:8(9):739-41. 508 SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes & Endocrinology. 2020;8(9):739-41.<br>509 42. Jimenez-Blanco S. Pla-Peris B. Marazuela M. COVID-19: a cause of recurrent
- 509 42. Jimenez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves'<br>510 hyperthyroidism? Journal of Endocrinological Investigation. 2021:44(2):387-8. 510 hyperthyroidism? Journal of Endocrinological Investigation. 2021;44(2):387-8.<br>511 43. Mateu-Salat M. Urgell E. Chico A. SARS-COV-2 as a trigger for autoim
- 511 43. Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of 512 two cases of Graves' disease after COVID-19. Journal of Endocrinological Investigation. 512 two cases of Graves' disease after COVID-19. Journal of Endocrinological Investigation.<br>513 2020:43(10):1527-8. 513 2020;43(10):1527-8.<br>514 44. Sahin M. Havn
- 514 44. Sahin M, Haymana C, Demirci I, Tasci I, Rifat E, Unluturk U, et al. The clinical outcomes of 515 COVID-19 infection in patients with a history of thyroid cancer: A nationwide study. Clinical 515 COVID-19 infection in patients with a history of thyroid cancer: A nationwide study. Clinical 516 Endocrinology 2021:95(4):628-37 516 Endocrinology. 2021;95(4):628-37.<br>517 45. Chai C. Feng X. Lu M. Li S.
- 517 45. Chai C, Feng X, Lu M, Li S, Chen K, Wang H, et al. One-year mortality and consequences of COVID-19 in cancer patients: A cohort study. Jubmb Life. 2021:73(10):1244-56. 518 COVID-19 in cancer patients: A cohort study. Iubmb Life. 2021;73(10):1244-56.<br>519 46. Cafiero C. Rosanene F. Palmirotta R. Re A. Ottaiano MP. Benincasa G. et a
- 519 46. Cafiero C, Rosapepe F, Palmirotta R, Re A, Ottaiano MP, Benincasa G, et al. Angiotensin System<br>520 Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and 520 Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and<br>521 Asymptomatic Patients: A Pilot Study. Pharmacogenomics & Personalized Medicine. 2021;14:621-9.
- 521 Asymptomatic Patients: A Pilot Study. Pharmacogenomics & Personalized Medicine. 2021;14:621-9.<br>522 47. Kouhpaveh HR. Tabasi F. Dehvari M. Naderi M. Bahari G. Khalili T. et al. Association betwee
- 522 47. Kouhpayeh HR, Tabasi F, Dehvari M, Naderi M, Bahari G, Khalili T, et al. Association between<br>523 angiotensinogen (AGT), angiotensin-converting enzyme (ACE) and angiotensin-II receptor 1 (AGTR1)
- 523 angiotensinogen (AGT), angiotensin-converting enzyme (ACE) and angiotensin-II receptor 1 (AGTR1)<br>524 polymorphisms and COVID-19 infection in the southeast of Iran: a preliminary case-control study.
- 524 polymorphisms and COVID-19 infection in the southeast of Iran: a preliminary case-control study.<br>525 Translational medicine communications. 2021:6(1):26.
- 525 Translational medicine communications. 2021;6(1):26.<br>526 48. Tenasse P-R. Vollenberg R. Steinebrev N. Koenig 526 48. Tepasse P-R, Vollenberg R, Steinebrey N, Koenig S. The Dysregulation of the Renin-Angiotensin<br>527 System in COVID-19 Studied by Serum Proteomics: Angiotensinogen Increases with Disease Severity. 527 System in COVID-19 Studied by Serum Proteomics: Angiotensinogen Increases with Disease Severity.<br>528 Molecules. 2022:27(8):2495.
- 528 Molecules. 2022;27(8):2495.<br>529 49. Naravan SS. Lorenz K. 529 49. Narayan SS, Lorenz K, Ukkat J, Hoang-Vu C, Trojanowicz B. Angiotensin converting enzymes<br>530 ACE and ACE2 in thyroid cancer progression. Neoplasma. 2020:67(2):402-9.
- 530 ACE and ACE2 in thyroid cancer progression. Neoplasma. 2020;67(2):402-9.<br>531 50. Egami K. Murohara T. Shimada T. Sasaki K. Shintani S. Sugava T. et al
- 531 50. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, et al. Role of host angiotensin<br>532 II type 1 receptor in tumor angiogenesis and growth. Journal of Clinical Investigation. 532 II type 1 receptor in tumor angiogenesis and growth. Journal of Clinical Investigation.<br>533 2003;112(1):67-75. 533 2003;112(1):67-75.<br>534 51. Xu J. Fang J.
- 534 51. Xu J, Fang J, Cheng Z, Fan L, Hu W, Zhou F, et al. Overexpression of the Kininogen-1 inhibits<br>535 proliferation and induces apoptosis of glioma cells. Journal of Experimental & Clinical Cancer 535 proliferation and induces apoptosis of glioma cells. Journal of Experimental & Clinical Cancer<br>536 Research. 2018;37:180.
- 536 Research. 2018;37:180.<br>537 52. Quesada-Calvo F. 537 52. Quesada-Calvo F, Massot C, Bertrand V, Longuespee R, Bletard N, Somja J, et al. OLFM4,<br>538 KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early
- KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early

- 539 colorectal cancer stages. Clinical Proteomics. 2017;14:9.<br>540 53. Lin L. Zeng X. Liang S. Wang Y. Dai X. Sun Y. e
- 540 53. Lin L, Zeng X, Liang S, Wang Y, Dai X, Sun Y, et al. Construction of a co-expression network<br>541 and prediction of metastasis markers in colorectal cancer patients with liver metastasis. Journal of
- 541 and prediction of metastasis markers in colorectal cancer patients with liver metastasis. Journal of 542 Gastrointestinal Oncology 2022:13(5):2426-38.
- 542 Gastrointestinal Oncology. 2022;13(5):2426-38.<br>543 54. Gever PE. Arend FM. Doll S. Louiset M.
- 543 54. Geyer PE, Arend FM, Doll S, Louiset M-L, Winter SV, Mueller-Reif JB, et al. High-resolution<br>544 serum proteome traiectories in COVID-19 reveal patient-specific seroconversion. Embo Molecular
- 544 serum proteome trajectories in COVID-19 reveal patient-specific seroconversion. Embo Molecular<br>545 Medicine. 2021:13(8):e14167.
- 545 Medicine. 2021;13(8):e14167.<br>546 55. Schmelter F. Foeh B. M 546 55. Schmelter F, Foeh B, Mallagaray A, Rahmoeller J, Ehlers M, Lehrian S, et al. Metabolic and<br>547 Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients.
- 547 Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients.<br>548 Frontiers in Molecular Biosciences. 2021:8:737039. 548 Frontiers in Molecular Biosciences. 2021;8:737039.<br>549 56. Souza Junior DR. Martins Silva AR. Rosa-Fern
- 549 56. Souza Junior DR, Martins Silva AR, Rosa-Fernandes L, Reis LR, Alexandria G, Bhosale SD, et al.<br>550 HDL proteome remodeling associates with COVID-19 severity. Journal of Clinical Lipidology.
- 550 HDL proteome remodeling associates with COVID-19 severity. Journal of Clinical Lipidology.<br>551 2021:15(6):796-804. 551 2021;15(6):796-804.<br>552 57. Sanders DW, Ju
- 552 57. Sanders DW, Jumper CC, Ackerman PJ, Bracha D, Donlic A, Kim H, et al. SARS-CoV-2 requires<br>553 cholesterol for viral entry and pathological syncytia formation. Elife. 2021;10:e65962. 553 cholesterol for viral entry and pathological syncytia formation. Elife. 2021;10:e65962.<br>554 58. Bornstein SR. Voit-Bak K. Donate T. Rodionov RN. Gainetdinov RR. Tselmin
- 554 58. Bornstein SR, Voit-Bak K, Donate T, Rodionov RN, Gainetdinov RR, Tselmin S, et al. Chronic<br>555 post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?
- 555 post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?<br>556 Molecular Psychiatry. 2022:27(1):34-7. 556 Molecular Psychiatry. 2022;27(1):34-7.<br>557 59. Moon H. Ruelcke JE. Choi E. Sha
- 557 59. Moon H, Ruelcke JE, Choi E, Sharpe LJ, Nassar ZD, Bielefeldt-Ohmann H, et al. Diet-induced<br>558 hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IOGAP1 and 558 hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1. Oncotarget. 2015;6(10):7438-53. 559 caveolin-1. Oncotarget. 2015;6(10):7438-53.<br>560 60. Shen Y. Wang C. Ren Y. Ye J. A comp
- 560 60. Shen Y, Wang C, Ren Y, Ye J. A comprehensive look at the role of hyperlipidemia in promoting colorectal cancer liver metastasis. Journal of Cancer. 2018:9(16):2981-6. 561 colorectal cancer liver metastasis. Journal of Cancer. 2018;9(16):2981-6.<br>562 61. Revilla G. de Pablo Pons M. Baila-Rueda L. Garcia-Leon A.
- 562 61. Revilla G, de Pablo Pons M, Baila-Rueda L, Garcia-Leon A, Santos D, Cenarro A, et al.<br>563 Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness. Sci Rep. 563 Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness. Sci Rep.<br>564 2019:9:10260.
- 564 2019;9:10260.<br>565 62. Guntur V 565 62. Guntur VP, Nemkov T, de Boer E, Mohning MP, Baraghoshi D, Cendali FI, et al. Signatures of 566 Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute 566 Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute<br>567 Sequelae of COVID-19 (PASC), Metabolites, 2022;12(11):1026.
- 567 Sequelae of COVID-19 (PASC). Metabolites. 2022;12(11):1026.<br>568 63. Fang S, Wang H, Lu L, Jia Y, Xia Z. Decreased complement
- 568 63. Fang S, Wang H, Lu L, Jia Y, Xia Z. Decreased complement C3 levels are associated with poor<br>569 prognosis in patients with COVID-19: A retrospective cohort study. International 569 prognosis in patients with COVID-19: A retrospective cohort study.<br>570 immunopharmacology. 2020:89(Pt A):107070. 570 immunopharmacology. 2020;89(Pt A):107070.<br>571 64. Jiang H, Chen Q, Zheng S, Guo C, Luo
- 57164. Jiang H, Chen Q, Zheng S, Guo C, Luo J, Wang H, et al. Association of Complement C3 with<br>572 Clinical Deterioration Among Hospitalized Patients with COVID-19. International Journal of General 572 Clinical Deterioration Among Hospitalized Patients with COVID-19. International Journal of General<br>573 Medicine. 2022:15:849-57.
- 573 Medicine. 2022;15:849-57.<br>574 65. Oin C. Zhou L. Hu 2 574 65. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in 575 Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases. 575 Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases.<br>576 2020:71(15):762-8.
- 576 2020;71(15):762-8.<br>577 66. Yekta RF, O
- 577 66. Yekta RF, Oskouie AA, Tavirani MR, Mohajeri-Tehrani MR, Soroush AR. Decreased<br>578 apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid 578 apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid<br>579 carcinoma: A proteomic study. International Journal of Biological Markers. 2018:33(4):455-62.
- 579 carcinoma: A proteomic study. International Journal of Biological Markers. 2018;33(4):455-62.<br>580 67. Mull B, Davis R, Munir I, Perez MC, Simental AA, Khan S. Differential expression of Vit 580 67. Mull B, Davis R, Munir I, Perez MC, Simental AA, Khan S. Differential expression of Vitamin D<br>581 binding protein in thyroid cancer health disparities. Oncotarget. 2021;12(7):596-607.
- 581 binding protein in thyroid cancer health disparities. Oncotarget. 2021;12(7):596-607.<br>582 68. Speeckaert MM. Speeckaert R. Delanghe JR. Vitamin D binding protein in C
- <sup>582</sup>68. Speeckaert MM, Speeckaert R, Delanghe JR. Vitamin D binding protein in COVID-19. Clinical



- 584 69. McLaughlin K-M, Bechtel M, Bojkova D, Muench C, Ciesek S, Wass MN, et al.
- 585 COVID-19-Related Coagulopathy-Is Transferrin a Missing Link? Diagnostics. 2020;10(8):539.<br>586 70. Suriawinata E. Mehta KJ. Iron and iron-related proteins in COVID-19. Clinical and Expe 586 70. Suriawinata E, Mehta KJ. Iron and iron-related proteins in COVID-19. Clinical and Experimental 587 Medicine. 2022:18:1-23.
- 587 Medicine. 2022;18:1-23.<br>588 71. Yadav D. Pvsn KI 588 71. Yadav D, Pvsn KK, Tomo S, Sankanagoudar S, Charan J, Purohit A, et al. Association of 589 iron-related biomarkers with severity and mortality in COVID-19 patients. Journal of Trace Elements 589 iron-related biomarkers with severity and mortality in COVID-19 patients. Journal of Trace Elements<br>590 in Medicine and Biology. 2022:74:127075.
- 590 in Medicine and Biology. 2022;74:127075.<br>591 72. Vollmy F, van den Toorn H, Chiozzi I 591 72. Vollmy F, van den Toorn H, Chiozzi RZ, Zucchetti O, Papi A, Volta CA, et al. A serum proteome<br>592 signature to predict mortality in severe COVID-19 patients. Life Science Alliance. 592 signature to predict mortality in severe COVID-19 patients. Life Science Alliance.<br>593 2021:4(9):e202101099. 593 2021;4(9):e202101099.<br>594 73. Upadhyai P, Shen
- 594 73. Upadhyai P, Shenoy PU, Banjan B, Albeshr MF, Mahboob S, Manzoor I, et al. Exome-Wide<br>595 Association Study Reveals Host Genetic Variants Likely Associated with the Severity of COVID-19 in 595 Association Study Reveals Host Genetic Variants Likely Associated with the Severity of COVID-19 in<br>596 Patients of European Ancestry. Life. 2022;12(9):1300. 596 Patients of European Ancestry. Life. 2022;12(9):1300.<br>597 74. Zheng J, Zhang Y, Zhao H, Liu Y, Baird D
- 597 74. Zheng J, Zhang Y, Zhao H, Liu Y, Baird D, Karim MA, et al. Multi-ancestry Mendelian<br>598 randomization of omics traits revealing drug targets of COVID-19 severity. Ebiomedicine. 598 randomization of omics traits revealing drug targets of COVID-19 severity. Ebiomedicine.<br>599 2022:81:104112. 599 2022;81:104112.<br>600 75. Abdullah M
- 600 75. Abdullah MI, Lee CC, Junit SM, Ng KL, Hashim OH. Tissue and serum samples of patients with 601 papillary thyroid cancer with and without benign background demonstrate different altered expression 601 papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. Peeri. 2016;4:e2450.
- 602 of proteins. Peerj. 2016;4:e2450.<br>603 76. Giusti L, Iacconi P, Ciregia
- 603 76. Giusti L, Iacconi P, Ciregia F, Giannaccini G, Donatini GL, Basolo F, et al. Fine-needle aspiration<br>604 of thyroid nodules: Proteomic analysis to identify cancer biomarkers. Journal of Proteome Research. 604 of thyroid nodules: Proteomic analysis to identify cancer biomarkers. Journal of Proteome Research.<br>605 2008:7(9):4079-88. 605 2008;7(9):4079-88.<br>606 77. Qu T, Li Y-P,
- 606 77. Qu T, Li Y-P, Li X-H, Chen Y. Identification of potential biomarkers and drugs for papillary<br>607 thyroid cancer based on gene expression profile analysis. Molecular medicine reports. 607 thyroid cancer based on gene expression profile analysis. Molecular medicine reports.<br>608 2016:14(6):5041-8.
- 608 2016;14(6):5041-8.<br>609 78. Deng J, Cai X 609 78. Deng J, Cai X, Chen Z. The putative mechanistic insights on how SARS-CoV-2 might influence<br>610 the outcomes in cancer patients. Experimental Hematology & Oncology. 2022;11(1):52.
- 610 the outcomes in cancer patients. Experimental Hematology & Oncology. 2022;11(1):52.<br>611



614

615 Note: The two datasets were provided by Westlake laboratory of life sciences and biomedicine, key laboratory of structural biology of Zhejiang province,

616 school of life sciences, Westlake University.

617 Abbreviations: COVID-19, coronavirus disease 2019; FFPE, formalin-fixed paraffin-embedded tissue; FNAB, fine-needle aspiration biopsy; FTC, follicular

618 thyroid cancer; PTC, papillary thyroid cancer

 $619$   $\alpha$  A total of 1133 patients were involved in the dataset. More than one samples could be collected from different nodules of one patient.

#### <sup>621</sup>**Figure legends**

- 622 Figure 1. The flow chart of the study.<br>623 Abbreviations: COVID-19. coronavi
- 623 Abbreviations: COVID-19, coronavirus disease 2019; DEP, differentially expressed protein; DTC, differentiated thyroid cancer: NT normal thyroid tissue.
- 624 differentiated thyroid cancer; NT normal thyroid tissue.<br>625
- 
- 625 626 Figure 2. The volcano map of DEPs in two comparisons, (a) COVID-19 vs. not infected, and (b) DTC<br>627 vs. NT. (c). The Venn diagram of DEPs from two expression matrices.
- 627 vs. NT. (c). The Venn diagram of DEPs from two expression matrices.<br>628 Note: The three DEPs with lowest  $p$ -value were displayed in the figure
- 628 Note: The three DEPs with lowest *p*-value were displayed in the figure.<br>629 Abbreviations: NT. normal thyroid tissue: DTC, differentiated thyroid ca
- 629 Abbreviations: NT, normal thyroid tissue; DTC, differentiated thyroid cancer.<br>630
- 631 631 Figure 3. The bubble charts of gene ontology. (a) biological process, (b) cellular component, and (c) molecular function. (d). The results of pathway enrichment analysis.
- 632 molecular function. (d). The results of pathway enrichment analysis.<br>633 Note: Pathways with *p*-value <0.001 were displayed in the chart. wh
- 633 Note: Pathways with *p*-value <0.001 were displayed in the chart, while other pathways could be found in the Supplementary data. 634 in the Supplementary data.<br>635
- 
- 635 636 Figure 4. The protein-protein interaction network of shared DEPs.<br>637 Note: Redder color indicates higher connectivity of the gene with
- 637 Note: Redder color indicates higher connectivity of the gene with other genes. Disconnected nodes<br>638 were removed from the diagram. 638 were removed from the diagram.<br>639
- 
- 640 640 Figure 5. (a) The 12 intersected hub genes identified with the eight algorithms in CytoHubba. (b) The co-expression map of 12 hub genes and their related genes.
- 641 co-expression map of 12 hub genes and their related genes.<br>642 Twelve hub genes were displayed in the inner circle while t
- 642 Twelve hub genes were displayed in the inner circle while the related genes were in the outer circle.<br>643 Abbreviations: EPC, edge percolated component; MCC, maximal clique centrality; MNC, maximu
- 643 Abbreviations: EPC, edge percolated component; MCC, maximal clique centrality; MNC, maximum neighborhood component.
- 644 neighborhood component.<br>645
- 
- 645 646 Figure 6. The ROC curve of 12 hub genes in diagnosis of (a) COVID-19 and (b) DTC.<br>647
- 
- 648 648 Figure 7. The associations of hub genes and COVID-19 and DTC<br>649 \* Direct evidence has been revealed between AGT and COVID-19
- <sup>649</sup>\* Direct evidence has been revealed between AGT and COVID-19.







Fold Enrichment

Pathway nam





preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



# **High degree**

Low degree

20

15

10

 $\overline{0}$ 

5



preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.09.28.24314528;](https://doi.org/10.1101/2024.09.28.24314528) this version posted September 29, 2024. The copyright holder for this



**Set Size**  $(b)$ **ALB LIPC APOH FGG** APOA1 ТĘ **SERPIND1** APOC<sub>2</sub> **APOM** SERPINC1 ITIH<sub>3</sub> APOB ITIH<sub>2</sub> **TTR** RBP4 **AMBP** GC APOA2 KNG1 **SERPINA1** APOC1  $C<sub>5</sub>$ **AHSG AGT**  $HP$ **SERPINA7**  $C<sub>3</sub>$ **HRG** APOC3 ASGR2 ITIH1  $CP$ 

### **Networks**

- Co-expression
- Co-localization
- **Physical interactions**
- Shared protein domains
- **Predicted**
- Genetic interactions

## **Functions**

- Plasma lipoprotein particle remodeling
- Protein-containing complex remodeling
- Enzyme inhibitor activity
- **Triglyceride-rich plasma lipoprotein particle**
- Plasma lipoprotein particle organization
- Protein-lipid complex subunit organization
- **Protein-lipid complex remodeling**





- AHSG AUC(95%CI): 0.78(0.74-0.82)
- APOA2 AUC(95%CI): 0.70(0.66-0.75)
- $\sim$  APOM AUC(95%CI): 0.68(0.63-0.73)
- C3 AUC(95%CI):  $0.72(0.67-0.77)$
- GC AUC(95%CI):  $0.77(0.72-0.81)$
- **ITIH2** AUC(95%CI): 0.76(0.72-0.81)
- KNG1 AUC(95%CI): 0.73(0.69-0.77)
- **SERPINA1** AUC(95%CI): 0.75(0.71-0.80)
- **SERPINC1** AUC(95%CI): 0.75(0.70-0.79)
- **TF** AUC(95%CI):  $0.80(0.76-0.84)$
- $-$  TTR AUC(95%CI): 0.78(0.73-0.82)

$$
0.6 \t\t 0.8
$$

 $1.0$ 

1-Specificities

